Examiner Cite

Initial* No Patent Number

Remove

Figures Appear

Pages,Columns,Lines where

Relevant Passages or Relevant

	Application Number		10586141	
	Filing Date		2007-07-02	
NFORMATION DISCLOSURE	First Named Inventor Mara		ROSSI et al.	
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1646	
	Examiner Name J. Se		Seharaseyon	
	Attorney Docket Numb	or	ROSSIM	

U.S. PATENTS

Code¹ Issue Date

Name of Patentee or Applicant

of cited Document

	Ι΄	1								
If you wisl	h to a	d additional U.S. Par	tent citatio	n inform	ation pl	l lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial* Cite No Publication Number			Kind Code ¹			of cited Decument			iges,Columns,Lines where elevant Passages or Relevant gures Appear	
	1									
If you wisl	h to a	dd additional U.S. Pul	blished Ap	plication	citatio	n information	please click the Ad	d butto	on. Add	
				FOREIG	SN PA1	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date Name of Patente Applicant of cited Document			Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	т.
	1	2004000811	wo		A1	2003-12-31	PHARMACIA CORPORATION			
	2	03051922	wo		A2	2003-06-26	LEK PHARMACEUTICA D.	LS D		
	3	0168818	wo		A2	2001-09-20	ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10586141
	Filing Date		2007-07-02
First Named Inventor Mara		Mara	ROSSI et al.
Art Unit			1646
Examiner Name J. Set		J. Set	haraseyon
	Attorney Docket Number		ROSSI10

4	0001440	Wo	A2	2000-01-13	CAMBRIDGE NEUROSCIENCE, INC.		
5	9526199	wo	A1	1995-10-05	CYTOMED, INC.		
6	9118983	wo	A1	1991-12-12	JUNGBAUER ALOIS	Corresponding to CA2064710.	×
7	2064710	СА	A1	1991-11-30	JUNGBAUER ALOIS	Corresponding to WO9118983.	×
8	03051921	wo	A1	2003-06-26	APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.		

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Тб
	1	Sambrook & Russel, 3rd edition, pages 15-53 and 15-54 (2001)	
	2	Reverse Phase Chromatography, from Amersham Biosciences, pages 62-63 (2001)	
	3	Cel filtration, from Amersham Biosciences, page 91 (2002)	

If you wish to add additional non-patent literature document citation information please click the Add button Add

	Application Number		10586141	
	Filing Date		2007-07-02	
INFORMATION DISCLOSURE	First Named Inventor	Mara	ROSSI et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1646	
	Examiner Name	J. Set	haraseyon	
	Attorney Docket Numb	er	ROSSI10	

	EXAMINER SIGNATURE								
Examiner Signature		Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

16e Kin Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard S13.) 3 "For Junpanese patent four counters, the indication of the year of the integer or temperate protect the serial runger for Empirical protects the serial runger for plasted document, 4 "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. 9 Applicant is to place a check mark here if Empirish languages the resistance to statistics.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10586141
Filing Date		2007-07-02
First Named Inventor Mara		ROSSI et al.
Art Unit		1646
Examiner Name J. Set		naraseyon
Attorney Docket Numb	ec	ROSSI10

CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1 98 1	n make	the	appropriate	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Allen C Vun

_

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

37.971

Tomas or and origination			
Signature	IACYI	Date (YYYY-MM-DD)	2011-10-25

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.